D-cycloserine for the treatment of ataxia in spinocerebellar degeneration

Masafumi Ogawa, Hiroshi Shigeto, Toshiyuki Yamamoto, Yasushi Oya, Keiji Wada, Toru Nishikawa, Mitsuru Kawai

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)


We studied the effects of D-cycloserine, a partial NMDA receptor allosteric agonist, on ataxia in patients with spinocerebellar degeneration. Fifteen Japanese ataxic patients enrolled in a 14-day single-blind trial of D-cycloserine (daily oral dose of 50 mg) following a 14-day single-blind placebo phase. At the end of the D-cycloserine administration, there was a significant reduction in the posture, gait and total score of the international cooperative ataxia rating scale and in the time for walking and speech tasks. D-Cycloserine was well-tolerated and no adverse effect was observed. D-Cycloserine may have therapeutic efficacy for spinocerebellar ataxia.

Original languageEnglish
Pages (from-to)53-56
Number of pages4
JournalJournal of the Neurological Sciences
Issue number1-2
Publication statusPublished - Jun 15 2003

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'D-cycloserine for the treatment of ataxia in spinocerebellar degeneration'. Together they form a unique fingerprint.

Cite this